Sector News

UK drugmakers back in spotlight as bidders free to return

November 24, 2014
Life sciences
Two of the UK’s biggest health care companies, AstraZeneca and Smith & Nephew, will be pushed into the spotlight again this week as bidding restrictions on their former suitors expire.
 
After a six-month cooling off period, US drugmaker Pfizer will be able to approach AstraZeneca again, while the American orthopaedic company Stryker will also be allowed to return for hip and knee replacement maker Smith & Nephew.
 
Stryker is understood to be still keen but unlikely to return immediately after the takeover deadline ends on Friday. It is expected to return next year.
 
Stryker is under pressure to do a deal as its orthopaedic rivals, Zimmer, Biomet and Johnson & Johnson have already struck their own blockbuster deals.
 
However, sources have called the Pfizer-AstraZeneca situation “dead” and said the US drugmaker is now focused on other opportunities. Pfizer was said to have turned its attentions to rival US drugmaker Actavis, but Actavis bulked up with its $66bn acquisition of Allergan. The Swiss biotech company Actelion has also been on its radar.
 
Meanwhile, AstraZeneca’s share price has risen on the back of a boost in its pipeline, making it unlikely that Pfizer would be able to afford the group, particularly now the tax benefits of a deal have been complicated by new US Treasury rules.
 
Takeover Panel rules require bidders to walk away for six months after a failed bid, but few return. The last occasion was in 2001 when French industrial group Lafarge returned for UK cement maker Blue Circle.
 
By Ashley Armstrong
 

comments closed

Related News

February 4, 2023

MedTrace receives U.S. patent for diagnosing the human heart

Life sciences

The U.S. Patent and Trademark Office issued a patent to MedTrace for their method of diagnosing the human heart via 15O-water PET. The patented method is the foundation of the company’s software aQuant, currently under development. Hendrik “Hans” Harms, PhD and Senior Scientist at MedTrace, and Jens Soerensen, Professor and Clinical Advisor to MedTrace, are the originators of the method.

February 4, 2023

Roche taps insider Teresa Graham for top pharma job as setbacks prompt M&A questions

Life sciences

Teresa Graham, currently head of global product strategy for Roche pharma, will become the division’s new CEO next month, Roche said Thursday. Simultaneously, Roche is elevating Levi Garraway, chief medical officer, to the executive committee.

February 4, 2023

J&J’s pharma group quietly works through global overhaul, with layoffs expected to reach multiple countries

Life sciences

Fierce Pharma has obtained internal documents and video of a town hall meeting conducted this week describing what J&J called a “comprehensive review” of its portfolio. Moving forward, J&J plans to operate its vaccines and infectious diseases outfits as one group, the executives explained.

How can we help you?

We're easy to reach